Latest Blogs

Don S. Dizon, MD, FACP, FASCO
May 05, 2021
Rare and Cured: A Conversation With Someone I Treated Years Ago
Many years ago I treated a patient with a rare sarcoma. We recently reconnected and she generously shared her experience of being treated for and now considered "cured" of her rare tumor, with a reminder that the cancer experience is unique to every individual.
Peter Paul Yu, MD, FASCO, FACP
May 04, 2021
The Prepared Mind: Looking to the Digital Future of Real-World Data
If luck, as Louis Pasteur noted, favors the prepared mind, how will oncologists not only prepare but extend cognitive capacity in an era where both medical knowledge and the scope of human endeavor that physicians must address continue to increase exponentially?
Guest Commentary
Apr 27, 2021
Should We Teach Cost-Effectiveness of Cancer-Related Therapies in Oncology Training?
With the current pace of progress in cancer care, urgent implementation of cost-effectiveness training curriculum in fellowship training programs will be indispensable, shares Dr. Samer Al Hadidi. 
International Perspectives
Apr 12, 2021
The Mentor Quest
"A successful mentorship is mutually beneficial for the mentor and mentee, where each party has to recognize and understand what the other is offering and whether it fits each career path," said Dr. Atlal Abusanad.
Subscribe to this column

Edward Paul Balaban, DO, FACP, FASCO

Edward P. Balaban, DO, FACP, FASCO, is the medical director for the Cancer Care Partnership with Penn State University Cancer Institute and professor of medicine at Penn State Hershey Cancer Institute. He has served as a Practice Guideline Implementation Network (PGIN) representative for Weight-Based Dosing Chemotherapy for Cancer Patients and Gastrointestinal Guideline Advisory Groups. Dr. Balaban is past president of the Pennsylvania Society of Oncology and Hematology. He serves as an ASCO delegate to the American Medical Association House of Delegates (AMA HOD).

Disclosure.

May 05, 2010
The beginnings of a new "guideline"
It seems like I've participated in every facet of the "ASCO guideline" process. During the past three years of being part of the HSC (now CPG) committee, I have been amazed to witness how complex and detailed developing a guideline can become. The manuscripts are reviewed at several levels and...
1 Comments

Pages